(E)-3-(trifluoromethyl)benzaldehyde oxime | 154238-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(trifluoromethyl)benzaldehyde oxime
• 英文别名: 3-(trifluoromethyl)benzaldehyde oxime；(NE)-N-[[3-(trifluoromethyl)phenyl]methylidene]hydroxylamine
• CAS: 154238-37-6
• 化学式: C₈H₆F₃NO
• 分子量: 189.137
• InChiKey: GIONPAPDKZQLTK-LFYBBSHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(trifluoromethyl)benzaldehyde oxime 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 144.0h， 生成 3-[1-(3-Trifluoromethyl-phenyl)-meth-(E)-ylideneaminooxy]-propionic acid
  参考文献：
  名称：

  Synthesis, antiinflammatory activity and molecular orbital studies of a series of benzylideneaminoxypropionic acids substituted on the phenyl ring

  摘要：

  An examination of the antiinflammatory properties of certain beta-aminoxypropionic acids A (AOPAs) previously synthe- sized as analogs of antiinflammatory drugs with an arylacetic structure B (ArAAs), indicated that the most active acid is the (E)-3-(benzylideneaminoxy)-propionic acid (1), which was found to possess an activity comparable to that of Diclofenac (8). In an attempt to verify whether appropriate substitutions on the aromatic ring of 1 can modulate the antiinflammatory properties of this class of drugs, a series of benzylideneaminoxypropionic acids (BAOPAs) were synthesized, in which the phenyl group is substituted, in its 3 possible positions, by groups possessing different electronic, steric, and lipophilic characteristics. The antiinflammatory activity of the new compounds was determined by carrageenan-induced rat paw edema, using Diclofenac (8) as the reference drug. The pharmacological results revealed that among the BAOPAs examined, the most active are the m-chloro (7b) and p-ethoxy (7p) substituted compounds, which exhibit an antiinflammatory activity comparable to that of 1. Quantum mechanical calculations were also carried out in order to gain insight into the possible correlations between the pharmacological activity observed and the electronic and conformational effects induced by the presence of the various substituents.

  DOI：

  10.1016/0223-5234(94)90123-6
• 作为产物：
  描述：

  3-三氟甲基苯甲醛 在 盐酸羟胺 作用下， 生成 (E)-3-(trifluoromethyl)benzaldehyde oxime
  参考文献：
  名称：

  光诱导电子转移条件下苯甲醛肟的结构对醛和腈形成的影响

  摘要：

  通过稳态（产物研究）和激光闪光光解方法研究了一系列苯甲醛肟（1a - o）的光敏反应的机理。纳秒激光闪光光解研究表明，只要电子转移的自由能（ΔG ET）良好，肟就可以通过电子转移机理与三重态苯二甲腈（3 CA）反应。通常，肟的氧化电位应低于2.0V。氧化电位大于2.0 V的取代苯甲醛肟猝灭3CA的速率与取代基和氧化电位无关。在这些条件下，最可能的机理是氢原子转移机理，因为该反应仅取决于OH键强度，这对于所有肟实际上都是相同的。产品研究表明，醛肟反应生成相应的醛和腈。醛途径中的重要中间体是亚氨基氧基，它是通过电子转移-质子转移（ET-PT）序列（对于具有低氧化电位的肟）或氢原子转移（HAT）途径（对于具有-OH的肟）形成的。较大的氧化电位）。提出腈是由中间体亚氨基形成的，这些亚氨基可以通过直接氢原子提取或通过电子转移质子转移序列形成。实验数据似乎支持直接氢原子的提取，这是淬灭速率对氧化电位的

  DOI：

  10.1021/jo061325m

文献信息

• Novel chemoenzymatic oxidation of amines into oximes based on hydrolase-catalysed peracid formation
  作者：Daniel Méndez-Sánchez、Iván Lavandera、Vicente Gotor、Vicente Gotor-Fernández

  DOI：10.1039/c7ob00374a

  日期：——

  chemoenzymatic process. This strategy is based on a two-step sequence developed in one-pot at 30 °C and atmospheric pressure. First, the formation of a reactive peracid intermediate occurs by means of a lipase-catalysed perhydrolysis reaction, and then this peracid acts as a chemical oxidising agent of the amines. A total of nine ketoximes were isolated in high purity after a simple extraction protocol (90–98%

  已经通过化学酶促方法描述了苄胺向相应肟的有效转化。此策略基于在30°C和大气压下在一锅中开发的两步顺序。首先，借助于脂肪酶催化的过水解反应发生反应性过酸中间体的形成，然后该过酸充当胺的化学氧化剂。通过简单的提取操作，总共可以分离出九种高纯度的酮肟（分离产率为90-98％），而对于11种合成的醛肟，则需要进一步的柱色谱纯化（分离产率为71-82％）。在所有情况下，均具有出色的选择性，为胺在短反应时间内（1小时）的氧化提供了一种实用的方法。电子因子值。
• [EN] A METHOD OF TREATING LIVER FIBROSIS<br/>[FR] MÉTHODE DE TRAITEMENT DE LA FIBROSE HÉPATIQUE
  申请人：PFIZER LTD

  公开号：WO2012114223A1

  公开（公告）日：2012-08-30

  The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention.

  本发明涉及一种使用本发明中的3-环烷基氨基吡咯烷衍生物治疗丙型肝炎和/或肝纤维化的方法。
• 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20050192302A1

  公开（公告）日：2005-09-01

  The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

  本发明涉及公式I的3-环烷胺基吡咯烷衍生物：（其中R1、R2、R3、R4、R5、R6、R7、X、Y和Z如本文所定义），这些衍生物可用作化学因子受体活性的调节剂。特别是，这些化合物可用作化学因子受体的调节剂，更具体地作为CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可能结合化学因子受体，例如CCR2和/或CCR5化学因子受体，并且可用于治疗与化学因子（例如CCR2和/或CCR5）活性相关的疾病，如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
• 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance
  申请人：Ma Zhenkun

  公开号：US20060166906A1

  公开（公告）日：2006-07-27

  Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.

  具有化学式（I）的化合物可用于治疗细菌感染，同时避免胃肠不耐受的风险。含有这些化合物的组合物以及使用这些化合物进行治疗的方法也被揭示。
• PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF
  申请人：Kim Dong Yeon

  公开号：US20140031364A1

  公开（公告）日：2014-01-30

  Disclosed are a phenyl-isoxazol derivative compound, which is useful as a treatment material for virus infection, especially, infection of an influenza virus, or its pharmaceutically acceptable derivative, a preparation method thereof, and an illness treatment pharmaceutical composition including the compound as an active ingredient.

  揭示了一种苯基异噁唑衍生物化合物，其可用作治疗病毒感染的治疗材料，特别是流感病毒感染，或其药学上可接受的衍生物，以及其制备方法和包括该化合物作为活性成分的疾病治疗药物组合物。